Cytlimic
Higashi-shinagawa
About Cytlimic
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $20.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2019)
- Website: cytlimic.comen
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/cytlimic-148282 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.